Infant Bacterial Therapeutics AB (publ) reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was SEK 123.07 million compared to SEK 65.45 million a year ago. Basic loss per share from continuing operations was SEK 9.95 compared to SEK 5.83 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
87.8 SEK | +0.46% | +4.03% | -2.44% |
1st Jan change | Capi. | |
---|---|---|
-2.44% | 108M | |
+5.31% | 70.44B | |
+10.97% | 8.94B | |
-16.83% | 4.75B | |
+43.48% | 4.5B | |
+3.20% | 3.85B | |
+18.82% | 2.38B | |
-21.36% | 2.34B | |
-29.67% | 2.2B | |
+8.38% | 1.96B |
- Stock Market
- Equities
- IBT B Stock
- News Infant Bacterial Therapeutics AB
- Infant Bacterial Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2023